Omnicell, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022; unaudited. Omnicell provides medication-management automation, software, and services to healthcare systems and pharmacies. It reports as one operating segment.
Financial results
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Total revenue | $318.8 million | $251.8 million | +27% |
| Product revenue | $225.9 million | $178.1 million | +27% |
| Services and other revenue | $93.0 million | $73.7 million | +26% |
| Gross profit / gross margin | $150.0 million / 47% | $122.3 million / 49% | Margin down 2 percentage points |
| Operating income / margin | $5.1 million / 1.6% | $19.6 million / 7.8% | Income down 74% |
| Net income | $8.2 million | $14.1 million | Down 42% |
| Diluted EPS | $0.17 | $0.30 | Down 43% |
| Operating cash flow | $(16.0) million | $57.4 million | Declined $73.4 million |
Revenue growth reflected higher demand, particularly for automated dispensing systems, as well as contributions from recent acquisitions to services revenue. Management attributed lower gross margin to service-business investment and inflation in inventory costs, partly offset by higher volumes and scale benefits. Operating expenses rose 41%, including increased employee-related costs, acquisition-related headcount, and investment in development and services. Q1 2022 results included a $1.8 million operating-lease asset impairment and $3.5 million of restructuring costs.
Balance sheet, debt, and liquidity
- Cash and cash equivalents were $265.0 million at March 31, 2022, versus $349.1 million at year-end 2021. Cash, cash equivalents, and restricted cash totaled $288.4 million.
- Current assets were $775.6 million and current liabilities $951.0 million; working capital was a deficit of $175.4 million and the current ratio was 0.8. Management says the deficit primarily reflects classification of the convertible notes as current.
- Convertible senior notes had $575.0 million principal and a $564.3 million carrying value, classified as current; their reported fair value was $810.5 million. The notes bear 0.25% interest and mature in September 2025. A stock-price trigger made them convertible at holders’ option during Q2 2022; the company elected to pay at least principal in cash on conversion.
- No borrowings were outstanding under the $500 million revolving credit facility, which expires in November 2024. The company reported compliance with its credit covenants.
- Cash fell by $67.3 million during the quarter. Investing used $18.7 million, including $11.5 million of property and equipment purchases, $3.9 million of external software development, and $3.4 million for the Hub and Spoke acquisition. Financing used $32.1 million, including $52.2 million of share repurchases.
- Non-cancelable purchase commitments totaled $227.1 million, of which $194.5 million was expected to be paid during 2022.
Material changes and unusual items
- Revenue increased 27% year over year, while operating income and net income declined materially and gross margin contracted.
- Operating cash flow turned negative, principally reflecting a $50.0 million increase in receivables, a $23.9 million decrease in accrued compensation, and a $17.3 million inventory build; higher deferred revenue partly offset these uses.
- Omnicell adopted ASU 2020-06 on January 1, 2022. This increased the notes’ carrying value and reclassified amounts between equity, retained earnings, and deferred taxes; it eliminated amortization of the notes’ prior debt discount. Adoption did not affect opening-period operations or cash flows.
- The company repurchased approximately 389,300 shares for $52.2 million at an average $134.11 per share; $2.7 million remained under the 2016 repurchase program at quarter-end.
- Q1 acquisitions included Hub and Spoke Innovations for approximately $3.4 million, intended to extend UK retail-pharmacy capabilities. Acquisitions completed in 2021 also contributed to the current-quarter comparison.
Outlook, commentary, and risks
The filing provides no specific quarterly or full-year 2022 revenue or earnings guidance. Management stated that cash, expected operating cash flows, employee-equity proceeds, and available revolver capacity should meet needs for at least the next 12 months. It expects cash uses for working capital, capital expenditures, acquisitions, contractual obligations, and possible share repurchases. Management also noted that results for this quarter are not necessarily indicative of the full year.
- Management described customer purchasing patterns as generally returning to pre-pandemic levels, but noted continuing uncertainty from COVID-19 and its effects on customers, suppliers, and operations.
- Supply-chain disruption, component availability, inflation, installation timing, and workforce capacity could affect costs, deliveries, and revenue recognition.
- On May 4, 2022, after quarter-end, the company identified ransomware affecting certain internal systems and some products and services. Its investigation was ongoing, and it could not determine the extent or potential financial impact.
- Legal matters included a BIPA class-action settlement pending final approval and a confidential settlement with Becton, Dickinson and Company, with obligations still being completed. The company reported no material accrual for the described proceedings.
- Risks also include uncertainty surrounding the 340B Drug Pricing Program, healthcare regulation and privacy requirements, foreign-exchange exposure, and the possibility of adverse litigation outcomes.
Key facts for investors to verify
- Whether revenue growth and customer demand persist, and how much growth reflects acquisitions versus organic performance.
- Whether margin pressure from inflation, service investment, and higher operating expenses eases or continues.
- Whether working-capital use, receivable collections, inventory levels, and operating cash flow improve.
- The potential cash and dilution consequences if holders convert the $575 million notes, and the company’s ability to manage their current classification and 2025 maturity.
- The operational, customer, financial, and disclosure effects of the May 2022 ransomware incident as the investigation develops.
- Final approval and financial consequences of the legal settlements, and developments affecting the 340B market.